HC Wainwright Issues Negative Forecast for MIST Earnings

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) – Stock analysts at HC Wainwright cut their Q1 2025 earnings estimates for Milestone Pharmaceuticals in a research note issued to investors on Monday, March 17th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($0.18) per share for the quarter, down from their prior forecast of ($0.17). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ Q2 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.02) EPS, FY2026 earnings at ($0.89) EPS and FY2027 earnings at ($0.02) EPS.

Milestone Pharmaceuticals Stock Down 16.4 %

Shares of MIST stock opened at $1.99 on Thursday. The firm’s fifty day moving average price is $2.02 and its two-hundred day moving average price is $1.81. Milestone Pharmaceuticals has a 1 year low of $1.12 and a 1 year high of $2.75. The company has a current ratio of 15.40, a quick ratio of 15.40 and a debt-to-equity ratio of 2.18. The firm has a market capitalization of $106.12 million, a P/E ratio of -2.46 and a beta of 1.83.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Jones Financial Companies Lllp grew its stake in shares of Milestone Pharmaceuticals by 1,000.0% in the fourth quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock valued at $26,000 after buying an additional 10,000 shares in the last quarter. National Bank of Canada FI grew its position in shares of Milestone Pharmaceuticals by 163.4% in the 4th quarter. National Bank of Canada FI now owns 18,700 shares of the company’s stock valued at $44,000 after acquiring an additional 11,600 shares during the period. PVG Asset Management Corp acquired a new position in shares of Milestone Pharmaceuticals during the 3rd quarter worth about $46,000. Atria Investments Inc raised its holdings in shares of Milestone Pharmaceuticals by 44.4% in the 3rd quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock valued at $61,000 after purchasing an additional 12,430 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new stake in Milestone Pharmaceuticals in the 4th quarter valued at about $73,000. 86.18% of the stock is owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.